Therapeutic DLL4 binding proteins

US9132190B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Lorenzo Benatuil · Northborough, US
• Erwin R. Boghaert · Pleasant Prairie, US
• Jijie Gu · Shrewsbury, US
• Maria Harris · Shrewsbury, US
• Jonathan A. Hickson · Lake Villa, US
• Chung-Ming Hsieh · Newton, US
• Yuliya Kutskova · Northborough, US
• Yingchun Li · 安丰镇, CN
• Zhihong Liu · Cupertino, US
• Susan Morgan-Lappe · Chicago, US

Key dates

• Filing date: Nov 26, 2013
• Grant date: Sep 15, 2015
• Expiry date: Nov 30, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.